Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics

Oncogene

Volumn 32, Issue 8, 2013, Pages 939-946

  Copeland, R A ^a   Moyer, M P ^a   Richon, V M ^a  

^a EPIZYME INC   (United States)

Author keywords

drug discovery; enzyme inhibitors; epigenetics; personalized therapeutics; protein methyltransferases

Indexed keywords

3 DEAZANEPLANOCIN; ANTINEOPLASTIC AGENT; AZ 505; DOT1L PROTEIN; EPZ 004777; EPZ 005687; FIBROBLAST GROWTH FACTOR RECEPTOR 3; HISTONE H3; HYDROLASE INHIBITOR; INDAZOLE DERIVATIVE; METHYLTRANSFERASE INHIBITOR; MIXED LINEAGE LEUKEMIA PROTEIN; PROTEIN METHYLTRANSFERASE; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; WHSC1 PROTEIN;

ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; CATALYSIS; CHROMOSOME TRANSLOCATION; CONCENTRATION RESPONSE; DRUG POTENCY; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; GENE TARGETING; HISTONE METHYLATION; HUMAN; LEUKEMIA; MOLECULARLY TARGETED THERAPY; NONHUMAN; PERSONALIZED MEDICINE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; TUMOR PROMOTION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DRUG DISCOVERY; ENZYME INHIBITORS; EPIGENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN METHYLTRANSFERASES;

EID: 84874789539     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.552     Document Type: Review

References (73)

1. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128: 693-705.
2. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000; 403: 41-45.
3. Allis CD, Berger S, Cote G, Dent SYR, Jenuwien T, Kouzarides T, et al. New nomenclature for chromatin-modifying enzymes. Cell 2007; 131: 633-636.
4. Copeland RA, Olhava EJ, Scott MP. Targeting epigenetic enzymes for drug discovery. Curr Opin Chem Biol 2010; 14: 505-510.
5. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 2012; 11: 384-400.
6. Copeland RA. Protein methyltransferase inhibitors as personalized cancer therapeutics. Drug Discov Today Ther Strategies 2011 (doi:10.1016/j.ddstr. 2011.08.001).
7. Copeland RA, Solomon ME, Richon VM. Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov 2009; 8: 724-732.
8. Richon VM, Johnston D, Sneeringer CJ, Jin L, Majer CR, Elliston K, et al. Chemogenetic analysis of human protein methyltransferases. Chem Biol Drug Des 2011; 78: 199-210.
9. Barski A, Cuddapah S, Cui K, Roh T-Y, Schones DE, Wang Z, et al. High-resolution profiling of histone methylations in the human genome. Cell 2007; 129: 823-837.
10. Webb KJ, Lipson RS, Al-Hadid Q, Whitelegge JP, Clarke SG. Identification of protein N-terminal methyltransferases in yeast and humans. Biochemistry 2010; 49: 5225-5235.
11. Copeland RA. Enzymes: A Practical Introduction to Structure, Mechanism and Data Analysis. 2nd edn. New York: Wiley, 2000.
12. Cheng X, Collins RE, Zhang X. Structural and sequence motifs of protein (histone) methylation enzymes. Annu Rev Biophys Biomol Struct 2005; 34: 267-294.
13. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol 2010; 28: 1069-1078.
14. Luo M. Current chemical biology approaches to interrogate protein methyltransferases. ACS Chem Biol 2012; 7: 443-463.
15. Feng Q, Wang H, Ng HH, Erdjument-Bromage H, Tempst P, Struhl K, et al. Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr Biol 2002; 12: 1052-1058.
16. Cao R, Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 2004; 14: 155-164.
17. Lee YH, Stallcup MR. Minireview: protein arginine methylation of nonhistone proteins in transcriptional regulation. Mol Endocrinol 2009; 23: 425-433.
18. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule dot1L inhibitor. Cancer Cell 2011; 20: 53-65.
19. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, et al. MLL-rearranged leukemia is dependent on aberrant h3k79 methylation by dot1L. Cancer Cell 2011; 20: 66-78.
20. Hess JL, Hug BA. Fusion-protein truncation provides new insights into leukemogenesis. Proc Natl Acad Sci USA 2004; 101: 16985-16986.
21. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007; 7: 823-833.
22. Slany RK. The molecular biology of mixed lineage leukemia. Haematologica 2009; 94: 984-993.
23. Ayton PM, Chen EH, Cleary ML. Binding to nonmethylated CpG DNA is essential for target recognition, transactivation, and myeloid transformation by an MLL oncoprotein. Mol Cell Biol 2004; 24: 10470-10478.
24. Slany RK, Lavau C, Cleary ML. The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX. Mol Cell Biol 1998; 18: 122-129.
25. Zeleznik-Le NJ, Harden AM, Rowley JD. 11q23 translocations split the 'AT-hook' cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene. Proc Natl Acad Sci USA 1994; 91: 10610-10614.
26. Muntean AG, Tan J, Sitwala K, Huang Y, Bronstein J, Connelly JA, et al. The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. Cancer Cell 2010; 17: 609-621.
27. He N, Chan CK, Sobhian B, Chou S, Xue Y, Liu M, et al. Human polymerase-associated factor complex (PAFc) connects the super elongation complex (SEC) to RNA polymerase II on chromatin. Proc Natl Acad Sci USA 2011; 108: E636-E645.
28. Lin C, Smith ER, Takahashi H, Lai KC, Martin-Brown S, Florens L, et al. AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol Cell 2010; 37: 429-437.
29. Benedikt A, Baltruschat S, Scholz B, Bursen A, Arrey TN, Meyer B, et al. The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures. Leukemia 2011; 25: 135-144.
30. Thiel AT, Blessington P, Zou T, Feather D, Wu X, Yan J, et al. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type mll allele. Cancer Cell 2010; 17: 148-159.
31. Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield VM, et al. hDOT1L links histone methylation to leukemogenesis. Cell 2005; 121: 167-178.
32. Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, et al. H3K79 methylation profiles define murine and human mll-af4 leukemias. Cancer Cell 2008; 14: 355-368.
33. Mahmoudi T, Boj SF, Hatzis P, Li VSW, Taouatas N, Vries RGJ, et al. The leukemiaassociated mllt10/af10-Dot1L are TCF4/b-catenin coactivators essential for intestinal homeostasis. PLoS Biol 2010; 8: e1000539.
34. Marango J, Shimoyama M, Nishio H, Meyer JA, Min DJ, Sirulnik A, et al. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood 2008; 111: 3145-3154.
35. Li B, Jackson J, Simon MD, Fleharty B, Gogol M, Seidel C, et al. Histone H3 lysine 36 dimethylation (H3K36me2) is sufficient to recruit the Rpd3s histone deacetylase complex and to repress spurious transcription. J Biol Chem 2009; 284: 7970-7976.
36. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998; 92: 3025-3034.
37. Keats JJ, Maxwell CA, Taylor BJ, Hendzel MJ, Chesi M, Bergsagel PL, et al. Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients. Blood 2005; 105: 4060-4069.
38. Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ, et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003; 101: 1520-1529.
39. Martinez-Garcia E, Popovic R, Min D-J, Sweet SMM, Thomas PM, Zamdborg L, et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 2011; 117: 211-220.
40. Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008; 647: 21-29.
41. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42: 181-185.
42. Sneeringer C, Scott MP, Kuntz K, Knutson SK, Pollock RM, Richon V, et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. ProceNatl Acad Sci USA 2010; 107: 20980-20985.
43. McCabe MT, Graves AP, Ganji G, Diaz E, Halsey WS, Jiang Y, et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci USA 2012; 109: 2989-2994.
44. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42: 722-726.
45. Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tonnissen ER, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010; 42: 665-667.
46. Ntziachristos P, Tsirigos A, Vlierberghe PV, Nedjic J, Trimarchi T, Flaherty MS, et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med 2012; 18: 298-303.
47. Mochizuki-Kashio M, Mishima Y, Miyagi S, Negishi M, Saraya A, Konuma T, et al. Dependency on the polycomb gene Ezh2 distinguishes fetal from adult hematopoietic stem cells. Blood 2011; 118: 6553-6561.
48. Chiang PK. Biological effects of inhibitors of S-adenosylhomocysteine hydrolase. Pharmacol Ther 1998; 77: 115-134.
49. Mori S, Iwase K, Iwanami N, Tanaka Y, Kagechika H, Hirano T. Development of novel bisubstrate-type inhibitors of histone methyltransferase SET7/9. Bioorg Med Chem 2010; 18: 8158-8166.
50. Yao Y, Chen P, Diao J, Cheng G, Deng L, Anglin JL, et al. Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies. J Am Chem Soc 2011; 133: 16746-16749.
51. Basavapathruni A, Jin L, Daigle SR, Majer CR, Therkelsen CA, Wigle TJ, et al. Conformational adaption drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L. Chem Biol Drug Des 2012; 80: 971-980.
52. Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 2006; 5: 730-739.
53. Copeland RA. Conformational adaptation in drug-target interactions and residence time. Future Med Chem 2011; 3: 1491-1501.
54. Onder TT, Kara N, Cherry A, Sinha AU, Zhu N, Bernt KM, et al. Chromatin-modifying enzymes as modulators of reprogramming. Nature 2012; 483: 598-602.
55. Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012; 8: 890-896.
56. Copeland RA, Richon VM, Scott MD, Sneeringer CJ, Kuntz KW, Knutson SK, et al. Inhibitors of human EZH2, and methods of use thereof. Patent Application WO2012034132, 2012.
57. Brackley J, Burgess JL, Grant S, Johnson N, Knight SD, LaFrance L, et al. Indoles WO2011140324, 2011.
58. Duquenne C, Johnson N, Knight SD, LaFrance L, Miller WH, Newlander K, et al. Indoles WO2011140325, 2011.
59. Burgess JL, Johnson N, Knight SD, LaFrance L, Miller WH, Newlander K, et al. Azaindazoles WO2012005805, 2012.
60. Knight SD, Miller WH, Newlander KA, Verma SK. Indoles WO2012075080, 2012.
61. Kubicek S, O'Sullivan RJ, August EM, Hickey ER, Zhang Q, Teodoro ML, et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell 2007; 25: 473-481.
62. Vedadi M, Barsyte-Lovejoy D, Liu F, Rival-Gervier S, Allali-Hassani A, Labrie V, et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol 2011; 7: 566-574.
63. Ferguson ALN, Howard T, Pollard H, Green I, Grande C, Cheung T, et al. structural basis of substrate methylation and inhibition of SMYD2. Structure 2011.
64. Purandare AV, Chen Z, Huynh T, Pang S, Geng J, Vaccaro W, et al. Pyrazole inhibitors of coactivator associated arginine methyltransferase 1 (CARM1). Bioorg Med Chem Lett 2008; 18: 4438-4441.
65. Allan M, Manku S, Therrien E, Nguyen N, Styhler S, Robert MF, et al. N-benzyl-1- heteroaryl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1). Bioorg Med Chem Lett 2009; 19: 1218-1223.
66. Huynh T, Chen Z, Pang S, Geng J, Bandiera T, Bindi S, et al. Optimization of pyrazole inhibitors of coactivator associated arginine methyltransferase (CARM1). Bioorg Med Chem Lett 2009; 19: 2924-2927.
67. Spannhoff A, Machmur R, Heinke R, Trojer P, Bauer I, Brosch G, et al. A novel arginine methyltransferase inhibitor with cellular activity. Bioorg Med Chem Lett 2007; 17: 4150-4153.
68. Jo SY, Granowicz EM, Maillard I, Thomas D, Hess JL. Requirement for Dot1L in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood 2011; 117: 4759-4768.
69. van Haaften G, Dalgliesh GL, Davies H, Chen L, Bignell G, Greenman C, et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 2009; 41: 521-523.
70. Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, et al. The genetic landscape of the childhood cancer medulloblastoma. Science 2011; 331: 435-439.
71. Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, Ding L, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 2012; 488: 43-48.
72. Harris WJ, Huang X, Lynch JT, Spencer GJ, Hitchin JR, Li Y, et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 2012; 21: 473-487.
73. Liu F, Chen X, Allali-Hassani A, Quinn AM, Wasney GA, Dong A, et al. Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. J Med Chem 2009; 52: 7950-7953.